Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

Key PointsViking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

Brasília Off

Martha Beck reports on those nominated for the Agriculture and Civil House in President Lula's fourth term. Edited by Patricia Xavier.

More from Friday 13 November →